Oncology biotech Monopar Therapeutics sets terms for $40 million IPO

Monopar Therapeutics, a Phase 3 biotech developing therapies for various types of cancer, announced terms for its IPO on Tuesday.

The Wilmette, IL-based company plans to raise $40 million by offering 4.4 million shares at a price range of $8 to $10. At the midpoint of the proposed range, Monopar Therapeutics would command a fully diluted market value of $130 million.

Monopar Therapeutics was founded in 2014 and plans to list on the Nasdaq under the symbol MNPR. JonesTrading is the sole bookrunner on the deal.

The article Oncology biotech Monopar Therapeutics sets terms for $40 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest IPOs Videos

    VersaBank Rings the Nasdaq Stock Market Closing Bell in Celebration of its IPO

    VersaBank (Nasdaq:VBNK), visits the Nasdaq MarketSite in Times Square.
    In honor of the occasion, David R. Taylor B.Sc. (Hons.), M.B.A., F.I.C.B., Director, President & CEO, rings the Closing Bell.

    Oct 5, 2021

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More